Brief: Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth And Pipeline Momentum
12/01/2026 13:35
Jan 12 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O: MIRUM PHARMACEUTICALS ANNOUNCES PRELIMINARY UNAUDITED 2025 RESULTS, DEMONSTRATING STRONG COMMERCIAL GROWTH AND PIPELINE MOMENTUM MIRUM PHARMACEUTICALS INC - PRELIM 2025 NET PRODUCT SALES OF APPROXIMATELY $520 MILLION EXCEED UPPER END OF GUIDANCE MIRUM PHARMACEUTICALS INC - 2026 EXPECTED GLOBAL NET PRODUCT SALES OF $630 MILLION TO $650 MILLION MIRUM PHARMACEUTICALS INC - VOLIXIBAT VISTAS STUDY IN PRIMARY SCLEROSING CHOLANGITIS (PSC) TOPLINE DATA EXPECTED Q2 2026 MIRUM PHARMACEUTICALS INC - LIVMARLI EXPAND STUDY IN ADDITIONAL CHOLESTATIC PRURITUS SETTINGS TIMING ACCELERATED; TOPLINE DATA NOW EXPECTED Q4 2026 MIRUM PHARMACEUTICALS - BLUEJAY THERAPEUTICS' AZURE-1 STUDY IN HDV INTERIM DATA EXPECTED IN Q2 2026, TOPLINE PHASE 3 DATA EXPECTED IN H2 2026 Source text: ID:nBw9vnK6qa Further company coverage: MIRM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mirum Pharmaceuticals
See all newsMirum Pharmaceuticals Q3 net product sales surge, outlook raised
Brief: Mirum Pharmaceuticals Announces Positive Results From Cohort 2 Of The Pivotal Progress Study Of Atebrioz™ (Zilurgisertib) In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva
Mirum climbs on positive late-stage trial results for liver disease drug
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX